Belite Bio, Inc American Depositary Shares
BLTEStock
$150.67+136.06%52W
Market Cap$5.88B
P/E—
Div yield—
Beta-1.20
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-18.43%
Price vs S&P 500 (4W)7.57%
VGM Score55.70
Market Capitalization$5.88B
Earnings Surprise History
Q1 26-0.68est. -0.65
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BLTEBelite Bio, Inc American Depositary Shares | — | — | C | $150.67 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Belite Bio is a clinical-stage biopharmaceutical company developing novel therapeutics for retinal degeneration and metabolic diseases. Its pipeline includes treatments for age-related macular degeneration, Stargardt disease, nonalcoholic fatty liver disease, type 2 diabetes, and gout.